
Conceptual illustration of C’ dot nanoparticles adapted with HER2-targeting antibody fragments (dark blue and green) and cancer-killing drugs (teal), entering a tumor cell via HER2 receptors (orange).
A novel cancer therapeutic, combining antibody fragments with molecularly engineered nanoparticles, permanently eradicated gastric cancer in treated mice, a multi-institutional team of researchers found.
The results of the “hit and run” drug delivery system, published in the March issue of Advanced Therapeutics, were the culmination of more than five years of collaboration between Cornell, the Memorial Sloan Kettering Cancer Center (MSKCC) and biopharmaceutical company AstraZeneca.
“I’ve seen beautiful results before, but I’ve never seen something that eradicates a tumor like this,” said study co-lead author Dr. Michelle Bradbury, MSKCC director of intraoperative imaging and professor of radiology at Weill Cornell Medicine.
The other co-lead authors are Ulrich Wiesner, the Spencer T. Olin Professor in the Department of Materials Science and Engineering, at Cornell Engineering; and J. Anand Subramony, vice president of protein engineering research and development at AstraZeneca at the time of the study.
Targeted cancer treatments such as antibody and nanoparticle therapies have seen narrow clinical use because of each therapy’s limitations, but the new therapeutic – an evolution of what the researchers call Cornell prime dots, or C’ dots – combines the best attributes of both into an ultrasmall, powerfully effective system.
As silica nanoparticles just 6 nanometers in size, C’ dots are small enough to penetrate tumors and safely pass through organs once injected into the body. Wiesner first developed them more than 15 years ago and, in collaboration with Bradbury, published a 2018 study that found an antibody fragment-nanoparticle hybrid to be especially effective in finding tumors.
This collaborative work with AstraZeneca set off the search for a new, molecularly engineered therapeutic version of this immuno-conjugate.
AstraZeneca “site engineered” fragments of antibodies so they would effectively attach to the C’ dots and target HER2 proteins associated with gastric cancer. The team optimized fragment conjugation to the C’ dot surface, along with specialized inhibitor drugs developed by AstraZeneca. This enabled the nanoparticles to carry about five times more drugs than most antibodies.
The final product was a version of C’ dots, armed with cancer-targeting antibody fragments and a large drug payload, all packed into a sub-7-nanometer, drug-immune conjugate therapy – a first of its kind in that size class, according to the researchers.
“We describe the mode of action as ‘hit and run,’” Wiesner said, “because the C’ dots either target the tumor microenvironment and kill the tumor cells or get safely cleared out of the body via renal clearance as a result of their small size, thereby minimizing off-target accumulation and associated side effects and toxicity.”
Mice with gastric cancer received three doses of the therapeutic. Not only did the treatment eradicate the disease in every mouse, but there was no evidence of tumor recurrence after nearly 200 days.
“Usually you’d have to couple the treatment with other therapies to see those kind of long-term results,” Bradbury said. “It showed that the very detailed, careful work of this team – the years spent on the stoichiometry and the surface chemical developments – it paid off.”
Bradbury underscored the versatility of the C’ dots platform, and said she envisions it being used not as a replacement for antibody treatments, but as a complementary tool that can be adapted to different types of cancers and other specific needs of patients.
“C’ dots have become unusually efficacious and safe in treating cancer. They completely obliterated the tumor, even at the cellular level,” said Wiesner. “This is what we ultimately had hoped for and it further supports our earlier decision to bet on therapeutic C’ dot applications.”
Wiesner and Bradbury said the research behind the new C’ dot therapeutic will be continued by Elucida Oncology, a startup company they founded to help bring the technology to market. They said that while Elucida is not using antibody fragments in their current clinical trial of C’ dots, the work will help them build new conjugates that can potentially utilize such fragments in future trials.
Original Article: Antibody fragment-nanoparticle therapeutic eradicates cancer
More from: Cornell University College of Engineering | Memorial Sloan Kettering Cancer Center
The Latest Updates from Bing News
Go deeper with Bing News on:
Cornell prime dots
- Selena Gomez's Polka-Dot Minidress Had the Most Dramatic Sleeves
Super-short hemlines call for an over-the-top detail.
- Best early October Prime Day deals to shop now
The October Prime Day event will be here soon. Amazon will celebrate Prime Big Deal Days on October 10 and October 11. The new retail holiday will be held in 19 countries, including the U.S., and ...
- Joining the dots: Mathematicians solve hot coloring problem
Strategic development In his most recent work, Dr. Liu and his collaborators successfully solved a problem proposed by mathematicians Hocquard, Lajou, and Lužar in the Journal of Graph Theory in ...
- Blue Dot
Best of Blue Dot: One of our greatest planetary astronomers: Heidi Hammel! August 25, 2023 • Host Dave Schlom is joined by special co-host Kendall Hall, an assistant physics professor at CSU ...
- A Viable Alternative to Conventional Lawn? Cornell May Have Found One.
Cornell Botanic Gardens is testing sustainable options for replacing your backyard grass. The bonus: They don’t need to be cut more than twice a year. By Margaret Roach It’s a grail of ...
Go deeper with Bing News on:
C’ dots
- ‘Dots for’ secures $670K to help Africa’s unconnected population benefit from digital economy
Japanese startup Dots for, the company aiming to help digitalizing rural villages in Africa with distributed communications using mesh network technology, announced on Friday that it has secured ...
- Dots for
Japanese startup Dots for, the company aiming to help digitalizing rural villages in Africa with distributed communications using mesh network technology, announced on Friday that it has secured 100 ...
- The Stock Market Looks Like the Dot-Com Boom Before the Bust
Tech has surged, the Fed is well into a tightening cycle, and yields on fixed-income securities have risen materially. Luckily, this is 2023, not 2000, and we know better now.
- Nordstrom’s N.Y.C. Flagship Just Doubled the Size of Its Men’s Shoe Department. Here’s a Look Inside.
Officially opening today, Nordstrom is celebrating the new space, located at 235 West 57th Street, with a party on Wednesday where customers will enjoy cocktails, light bites, a DJ set by ...
- Zoë Kravitz Wore a Micro-Mini Polka-Dot Dress in a Rare Sighting With Channing Tatum
Planned or not, Zoë donned a micro-mini, ruched black-and-white polka-dot dress, which she layered under a black oversized blazer (Her boyfriend's? I guess we'll never know.) She paired the LBD with ...